Known targets — ChEMBL curated mechanism
FGFR1FGFR2FGFR3FGFR4FLT1FLT4KDRPDGFRAPDGFRB
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL632500 | 0.98 | ALDH1A1 (0.35) | ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10 | |
| SCHEMBL27541297 | 0.95 | ALDH1A1 (0.34) | ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10 | |
| Ethane SCHEMBL17593441 | 0.95 | ALDH1A1 (0.37) | ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10 | |
| SCHEMBL2511955 | 0.95 | ALDH1A1 (0.37) | ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10 | |
| SCHEMBL1007938 | 0.95 | ALDH1A1 (0.37) | ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10 | |
| SCHEMBL3294493 | 0.95 | ALDH1A1 (0.37) | ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10 | |
| SCHEMBL27719314 | 0.94 | HSD17B10 (0.37) | ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10 | |
| SCHEMBL28248770 | 0.93 | POLB (0.37) | ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10 | |
| SCHEMBL28790654 | 0.92 | POLB (0.38) | ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10 | |
| SCHEMBL83682 | 0.92 | POLB (0.38) | ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 404 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2345713-A1 | A CONCENTRATED CULTURE SOLUTION AND APPLICATION METHOD THEREOF | Shanghai CP Guojian Pharmaceutical Co. Ltd (CN) | 2011-07-20 | — | — | EP | claimed |
| CN-118317947-A | Sortilin inhibitors | 索蒂纳制药股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118302162-A | Small molecule inhibitors of KRAS muteins | 默沙东有限责任公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118265710-A | Pyridine compounds as KV7.2 enhancers | 伊卡根有限责任公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-118103379-A | Solid forms of spirocyclic APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-113453760-B | APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-111989400-B | Alpha-amylase, compositions and methods | 丹尼斯科美国公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-118043339-A | Antimicrobial peptidomimetics | 巴斯利尔药物阿尔施维尔国际股份公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-118043041-A | LPAR1 antagonists and uses thereof | 康蒂内乌姆医疗公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-118043044-A | Allosteric ketene inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease | 佩特拉制药公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-1816337-A | Naphthalene-containing melanocortin receptor-specific small molecule | PALATIN TECHNOLOGIES INC (US) | 2006-08-09 | — | — | CN | disclosed |
| CN-1263758-C | 3, 7-diazabicyclo [3.3.0] octane and its use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-07-12 | — | — | CN | disclosed |
| CN-1745085-A | Novel tetracyclic heteroatom containing derivatives as selective estrogen receptor modulators | ORTHO MCNEIL PHARM INC (US) | 2006-03-08 | — | — | CN | disclosed |
| CN-1229350-C | New azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2005-11-30 | — | — | CN | disclosed |
| WO-2005095448-A2 | METHOD OF SYNTHESIZING AND PURIFYING DKK PROTEINS AND DKK PROTEINS OBTAINED THEREBY | OSCIENT PHARMACEUTICALS CORPORATION (US) | 2005-10-13 | — | — | WO | disclosed |
| CN-1620457-A | tetracyclic heterocyclic compounds as estrogen receptor modulators | ORTHO MCNEIL PHARM INC (US) | 2005-05-25 | — | — | CN | disclosed |
| CN-1608063-A | Indolinone derivatives useful as protein kinase inhibitors | THERAVANCE INC (US) | 2005-04-20 | — | — | CN | disclosed |
| US-20050064388-A1 | Methods and compositions for treating atheroma, tumors and other neoplastic tissue | UNIVERSITY OF TEXAS | 2005-03-24 | — | — | US | disclosed |
| CN-1489592-A | 3, 7-diazabicyclo [3.3.0] octane and its use in the treatment of cardiac arrhythmias | — | 2004-04-14 | — | — | CN | disclosed |
| CN-1440407-A | Bispidine compounds and their use in treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-09-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050064388-A1 | Methods and compositions for treating atheroma, tumors and other neoplastic tissue | NR1H3, GSTK1, NR1H2 | ALDH1A1 1150/4885KDM4E 4690/4885POLB 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.